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Abstract
The association between inflammation and lung tumor development has been clearly demonstrated. However,
little is known concerning the molecular events preceding the development of lung cancer. In this study, we char-
acterize a chemically induced lung cancer mouse model in which lung cancer developed in the presence of sili-
cotic chronic inflammation. Silica-induced lung inflammation increased the incidence and multiplicity of lung
cancer in mice treated with N -nitrosodimethylamine, a carcinogen found in tobacco smoke. Histologic and molec-
ular analysis revealed that concomitant chronic inflammation contributed to lung tumorigenesis through induction
of preneoplastic changes in lung epithelial cells. In addition, silica-mediated inflammation generated an immuno-
suppressivemicroenvironment inwhichweobserved increased expression of programmed cell death protein 1 (PD-1),
transforming growth factor–β1, monocyte chemotactic protein 1 (MCP-1), lymphocyte-activation gene 3 (LAG3),
and forkhead box P3 (FOXP3), as well as the presence of regulatory T cells. Finally, the K-RAS mutational profile
of the tumors changed from Q61R to G12D mutations in the inflammatory milieu. In summary, we describe some
of the early molecular changes associated to lung carcinogenesis in a chronic inflammatory microenvironment
and provide novel information concerning the mechanisms underlying the formation and the fate of preneoplastic
lesions in the silicotic lung.
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Introduction
Lung cancer is the leading cause of cancer-related mortality in the
world, causing more deaths per year than the next two more deadly
cancers combined [1]. A number of lung cancer etiological factors have
been clearly identified: tobacco smoke, primarily, but also cooking oil
vapor, burning coal, radon, air pollution, and occupational exposure to
asbestos and other carcinogens [2]. Most of these insults also trigger
pulmonary inflammation, which appears to exhibit dysregulation in
parallel to the carcinogenic process [3,4]. Interestingly, several studies
have shown that long-term consumption of anti-inflammatory drugs,
such as aspirin and specific cyclooxygenase-2 inhibitors, are associated
with a reduced incidence of lung cancer [5,6]. Failure to control the
inflammatory response is associated with active recruitment of stromal
and inflammatory cells that, in turn, change the tumor microenviron-
ment. The continuous infiltration of these cells incites tissue reparative
proliferation in cytokine- and growth factor–enriched stroma [7]. All of
these events may lead to sequential preneoplastic changes of the respira-
tory epithelium; some of these changes will eventually develop into lung
carcinoma [8]. In fact, inflammation and carcinogenesis share common
mechanistic hallmarks [9]. Importantly, chronic inflammation is also
associated with the induction of immune-suppressive mechanisms, such
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as the accumulation of myeloid-derived suppressor cells and regulatory
T cells (Tregs). These cell types inhibit antitumor immunity by block-
ing the activation of immune effector cells [10–12]. The blockade of
the programmed cell death protein 1 (PD-1)/PD-L1 axis, which nega-
tively regulates T cell responses, has recently been shown to provide
clinical benefit in patients with advanced non–small cell lung cancer,
with durable response in 6% to 18% of the treated cases [13,14].
The contribution of known oncogenes and tumor suppressor genes
to lung carcinogenesis has been demonstrated in previous reports
using genetically engineered mouse models [15]. However, additional
animal models that analyze the effects of airway inflammatory con-
ditions upon cellular and molecular events in lung carcinogenesis
are needed [16]. In this study, we developed a chemically induced
lung cancer model to study the role of chronic inflammation in lung
carcinogenesis. For that purpose, we used a low tumorigenic dose of
N -nitrosodimethylamine (NDMA) in combination with oropharyn-
geal administration of silica. Our model is unique in both the type of
inflammatory condition we use to promote cancer and the sequential
analysis of malignant lesions that allows us to study separately the
effects of inflammation in preneoplastic and full neoplastic lesions.
Silicosis is an occupational health concern. About 3 million workers
in Europe were exposed to crystalline silica from 1990 to 1993. Silica
exposure has been associated with several disorders, among which air-
way obstruction (chronic obstructive pulmonary disease) and lung
cancer are related to our model. Several meta-analysis generally demon-
strate a significant increased risk of lung cancer in patients with silicosis
[17]. In mice, silica induces a permanent inflammatory condition in
lungs, and marked cellular and stromal changes occur within lung
parenchyma; however, it does not lead to lung carcinogenesis [18].
In this study, we show that the inflammatory microenvironment
induced by silica markedly increases the incidence and multiplicity of
preneoplastic adenomatous lesions and lung adenocarcinoma in mice
treated with NDMA. Our findings also indicated that inflammation
promotes distinct mutational alterations and, interestingly, increases
the number of Tregs in lung stroma. Microarray-based gene expression
analysis revealed that, in the presence of silica, lung tumor cellsmarkedly
overexpress immunosuppressive genes.
Taken together, our study provides a useful new multistep animal
model for examining the specific role of chronic inflammation in
promoting lung carcinogenesis and identifies for the first time molec-
ular mechanisms by which silica-mediated inflammation creates a
favorable microenvironment for tumor progression.
Materials and Methods
Animal Model and Reagents
Eight-week-old female Balb/c mice were purchased from Harlan
Laboratories (Indianapolis, IN). All mouse experiments were approved
by the Ethics Committee on Animal Research of the University
of Navarra.
Both NDMA (Sigma, St Louis, MO) and silica (US Silica Co,
Berkeley Springs, WV) were resuspended in neutral-buffered saline
and sonicated for 30 seconds. Mice were treated with oropharyngeal
aspiration with a single dose of 7.5 mg/kg NDMA, 9 mg of silica, a
combination of both, or saline in a final volume of 90 μl, as pre-
viously described [19]. The NDMA dose was determined as the min-
imal amount of carcinogen able to induce lung tumorigenesis in mice
without toxic side effects (data not shown). The amount of instilled
silica was chosen as a dose that triggers lung inflammation with
minimal toxic side effects (data not shown).
Samples
Plasma samples and mouse lungs were obtained on months 2, 4,
6.5, 9, and 12 after treatment. Representative lung lobes were ligated,
sectioned, and rapidly frozen in liquid nitrogen. The remaining
material was fixed by immersion in 4% formaldehyde for 24 hours,
embedded in paraffin, sectioned along the main bronchial axis, and
cut at 3-μm thickness for immunohistochemical analysis.
At the time of analysis, 20-μm thickness cryostat sections of the
frozen lobe were obtained and lesions were microdissected by laser
capture microdissection (Leica, Wezlar, Germany). RNA and DNA
from microdissected tissues were extracted using RNeasy Kit (Qiagen,
Valencia, CA) and DNA Mini Kit (Qiagen), respectively.
Lesion Analysis
Tumor incidence was assessed microscopically in a representative
set of six sections per mouse including all of the lung lobes. Tumor
areas were calculated using the formula: A (μm2) = π × L × W , where
L is the largest diameter and W is the largest diameter perpendicular
to L. Tumors were classified as adenoma (solid or papillary) or adeno-
carcinoma, in accordance with the criteria previously published [20].
Cytokine Measurement
The concentrations of TNF-α, macrophage inflammatory protein-1α
(MIP-1α), interferon gamma-induced protein 10 (IP-10), interleukin-1
beta (IL-1β), IL-6, granulocyte-macrophage colony-stimulating factor
(GM-CSF), IL-10, IL-13, interferon gamma (INF-γ), and IL-12
(p40) were determined in plasma using a mouse Milliplex MAP Kit
(Millipore, Madrid, Spain) following the manufacturer’s instructions.
Immunostaining
Immunostaining was performed using antibodies raised against
mouse p-H2AX (1:50; Cell Signaling Technology, MA), mouse
pro-SPC (1:500; Abcam, Cambridge, MA), CC10 (1:4000; Upstate,
Billerica, MA), mouse Ki-67 (1:25; Neomarkers, Fremont, CA), mouse
CD31 (1:40; Dianova, Hamburg, Germany), mouse cleaved caspase-3
(1:100; Cell Signaling Technology, Danvers, MA), mouse forkhead
box P3 (FOXP3; 1:50; ebiosciences, Frankfurt, Germany), and Retnla
(1:250; Abcam). Heat-mediated antigen retrieval was used for anti-
bodies against Ki-67, CD31, cleaved caspase-3, FOXP3, and Retnla
by microwave exposure for 15 minutes at 800 W and 15 minutes at
375 W in 10 mM sodium citrate (pH 6). Incubations with anti-CC10
and anti-Retnla antibodies were followed by incubation with the
indirect avidin-biotin-peroxidase system (Dako, Barcelona, Spain).
In the case of p-H2AX, pro-SPC, Ki-67, CD31, cleaved caspase-3,
and FOXP3 immunostaining, Envision signal enhancement method
(Dako) was used. Slides were washed in TBS and peroxidase activity
was detected with 3-3′-diaminobenzidine (Dako). Slides were counter-
stained with Harris’ hematoxylin. Omission of the primary antibodies
was used as a negative control in one slide from each staining series.
p-H2AX, pro-SPC, Ki-67, cleaved caspase-3, and FOXP3 immuno-
staining was evaluated by two independent and blinded observers
and scored as the mean of the percentages of stained cells in 20 high-
power fields (×400). Quantification of CD31 staining was calculated
as the mean of the ratio between CD31-positive area and total area
using the Analysis software (Olympus, Barcelona, Spain).
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Immunohistochemistry to detect mouse CD4, CD8, CD3, CD20,
myeloperoxidase, and CD68 was performed using FLEX Ready-to-Use
specific antibodies (Dako) according to the manufacturer’s conditions.
Mutation Analysis
Mutations in K-RAS (codons 12 and 61), STK11 (exons 1-5, 8,
and 9), and TP53 (exons 5, 6, 7, 8, and 9) genes were analyzed in
DNA from microdissected malignant tissues by polymerase chain
reaction (PCR) amplification and sequencing. Genes were analyzed
in DNA from microdissected malignant tissues. DNA was amplified
by PCR using the primers shown in Table W1. After PCR ampli-
fication, exons upstream and downstream were sequenced using a
BigDye Terminator 3.1 sequencing instrument (Applied Biosystems,
Carlsbad, CA); sequences were then compared to a control sequence
with SeqScape v2.5 (Applied Biosystems). When a mutation was
detected, an additional amplification and sequencing experiment was
performed to confirm the result.
Expression Arrays
Gene expression profiles were analyzed in 16 individual lesions
(9 adenomas and 7 adenocarcinomas) from NDMA-silica–treated
mice and 10 individual lesions (5 adenomas and 5 adenocarcinomas)
from NDMA-only–treated mice. RNA was obtained from micro-
dissected tissue of at least eight consecutive 20-μm sections from each
frozen tissue block and retrotranscribed. Gene expression was ana-
lyzed using a microarray platform containing 28,122 mouse genes
(Oryzon Genomics, Barcelona, Spain) following the manufacturer’s
instructions. For control, cDNA from normal lung was used in
all hybridizations.
Normalization of every individual array was performed using the
lowest scatterplot smoother implemented in Matlab software as previ-
ously described [21]. All of the probes of the array, aside from controls,
were used for normalization; the fraction of the data used for smoothing
at each point was set to 5%. After calculation of the fold change values,
a filtering process was applied to eliminate low expression spots. The
criterion of ∣FC∣ > 2 in at least one of the samples reduced the number
of probes to 33,611 (corresponding to approximately 11,200 genes).
Statistics
Differences between two groups were analyzed using the Mann-
Whitney U test. To determine differences between more than two
experimentally independent groups, Kruskal-Wallis H test was chosen.
Figure 1. Effects of oropharyngeal administration of silica on mouse lungs. The left panel shows the histologic analysis of lung silica-
induced chronic inflammation in sections stained with hematoxylin and eosin. Silica alone–treated mice were sacrificed at months 2 (n=
4), 4 (n= 4), 6.5 (n= 4), 9 (n= 4), and 12 (n= 4) after treatment. Lungs were harvested and all the lung lobes were analyzed (one field per
lobe). (A–E) Silicotic granulomas at different experimental points following silica treatment. Insets show the details of the granulomatous
proliferations. (F–O) Alveolar (F–J) and bronchiolar (K–O) hyperplasia in areas close to the granulomas at 2, 4, 6.5, 9, and 12 months after
silica treatment. Alveolar proteinosis (J), hyperplastic goblet cells (N), and perivascular, peribronchiolar inflammatory reaction (asterisk, O)
and lung fibrotic lesions (data not shown) are common features in this model. Images were obtained at the same magnification. The right
panel includes representative examples of p-H2AX staining in lungs from NDMA-only– and NDMA-silica–treated mice. Samples were
considered positive when six or more cells presented positive immunoreactivity in at least two of three fields analyzed (×40).
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Chi-square test with Fisher correction was applied to study differences
between mutational profiles.
Differential gene signatures in expression array experiments were
identified using Linear Models for Microarray data [22]. Genes
were selected as significant using a B statistic cutoff (B > 0). A thresh-
old of ∣Z∣ > 2.3 (P value < .01) was chosen to select genes for
further analysis. R/Bioconductor [23] was used for preprocessing
and statistical analysis. Functional enrichment analysis of Gene
Ontology (GO) categories was conducted using Database for Annota-
tion, Visualization and Integral Discovery [24], and the biologic inter-
pretation was complemented through use of Ingenuity Pathway
Analysis (Ingenuity Systems, Redwood City, CA), in which the data-
base includes manually curated and fully traceable data derived from
literature sources.
Results
Silica Strongly Promotes an Inflammatory Process, DNA
Damage, and Pulmonary Fibrosis in Mouse Lungs
We first performed a histologic evaluation of the inflammatory
response in lungs from mice treated with silica (Figure 1, A–O). Lung
chronic inflammation was confirmed 2, 4, 6.5, 9, and 12 months after
treatment in all silica-treated mice irrespective of NDMA adminis-
tration; moreover, time-dependent progression of inflammation was
clearly observed. In particular, 2 months after silica administration,
nodular silicotic granulomas accompanied by marked epithelial hyper-
plasia were found in central areas close to branching and terminal
bronchioles in all lung lobes from all treated mice (Figure 1, A, F ,
and K ). Four months after treatment, inflamed regions were observed
in the same lung areas; however, the size of the lesions was markedly
larger. Granulomas were confluent and included large acellular centers
with peripheral infiltration of lymphocytes. Moderate bronchiolar
hyperplasia and hyperplastic type II pneumocytes were also observed
surrounding the silicotic lesions (Figure 1, B, G , and L). After 6.5
and 9 months, silicotic granulomas remained similar in size to those
observed after 4 months and exhibited larger central necrotic areas.
Parenchyma between silicotic nodules presented increased alveolar pro-
teinosis and thickened alveolar septa; epithelial hyperplasia persisted in
the vicinity as well as between the granulomas, and extensive areas of
hyperplastic goblet cells were also observed. Interestingly, there was a
marked increase of macrophages and lymphocytes in the perivascular
and peribronchiolar areas in comparison to lesions atmonth 4 (Figure 1,
C , D, H , I , M , and N ). Granulomas at month 12 exhibited larger
central necrotic areas. At this time point, the relative abundance of
epithelial hyperplasia was reduced, whereas macrophages and lympho-
cytes persisted in perivascular and peribronchiolar areas (Figure 1, E ,
J , and O). To characterize the inflammatory infiltrate in lungs from
NDMA-only–, silica-, and NDMA-silica–treated mice, the presence
of CD4 and CD8 T lymphocytes, total T lymphocytes, B lymphocytes,
polymorphonuclear leukocytes, and monocyte/macrophage cells was
evaluated by immunohistochemistry 2, 4, and 6.5 months after treat-
ment. All these cell populations were significantly increased in lungs
from silica-treated mice irrespective of NDMA administration in all
of the experimental time points analyzed (Table 1 and Figure W1).
NDMA administration did not affect inflammatory structural pheno-
type and leukocyte infiltration in lungs from mice treated with both
silica and saline. In addition to the histopathologic analysis, we mea-
sured TNF-α, MIP-1α, IP-10, IL-1β, IL-6, GM-CSF, IL-10, IL-13,
INF-γ, and IL-12 (p40) plasma concentrations. According to previous
findings [25], silica-treated mice presented significantly higher levels of
the pro-inflammatory cytokines TNF-α, MIP-1α, and IP-10 in com-
parison to the non–silica-treated counterparts. No significant differ-
ences in IL-1β, IL-6, GM-CSF, IL-10, IL-13, INF-γ, and IL-12
(p40) plasma levels were found between experimental groups
(Figure W2). However, we found a significant increase of mRNA ex-
pression of IL-6 and GM-CSF in lungs from NDMA-silica when com-
pared to NDMA-only–treated mice 12 months after treatment,
whereas no significant differences between both experimental groups
were found for IL-1β (Figure W3).
Table 1. Immunohistochemical Characterization of Leukocyte Infiltrate in Lungs from Mice Treated with NDMA, Silica, and NDMA-Silica.
Cell Type Marker Time
(Months)
Treatment*
NDMA
(Mean ± SD)‡
Silica
(Mean ± SD)‡
NDMA-Silica
(Mean ± SD)‡
P Value†
CD4 T lymphocytes CD4 2 1.13 ± 0.95 5 ± 1.18 3.96 ± 0.8 .015
4 1.04 ± 0.42 4.17 ± 1.18 4.38 ± 1.85 .022
6.5 0.83 ± 0.68 3.73 ± 1.08 5 ± 1.52 .018
CD8 T lymphocytes CD8 2 1.25 ± 0.48 8.75 ± 1.68 8.13 ± 1.72 .022
4 1.04 ± 0.42 7.71 ± 1.42 8.13 ± 1.72 .022
6.5 0.83 ± 0.68 6.88 ± 1.58 7.5 ± 1.8 .023
T lymphocytes CD3 2 0.92 ± 0.55 7.71 ± 1.42 8.33 ± 0 .017
4 1.25 ± 0.48 9.79 ± 3.87 7.5 ± 1.18 .02
6.5 0.92 ± 0.7 10.42 ± 1.77 10.28 ± 3.15 .048
B lymphocytes CD20 2 0 ± 0 1.88 ± 0.42 2.08 ± 0.48 .011
4 0.21 ± 0.42 2.29 ± 0.42 3.75 ± 1.08 .001
6.5 0.21 ± 0.42 3.33 ± 1.52 3.96 ± 0.42 .019
Polymorphonuclear leukocytes Myeloperoxidase 2 0.11 ± 0.19 2.29 ± 0.83 1.92 ± 0.17 .032
4 0.17 ± 0.19 2.92 ± 0.48 3.33 ± 1.18 .022
6.5 0.17 ± 0.19 3.13 ± 0.42 3.75 ± 1.08 .022
Monocyte/macrophage CD68 2 0.21 ± 0.42 2.5 ± 0.68 2.08 ± 0.48 .019
4 0.21 ± 0.42 5.83 ± 2.26 7.71 ± 3.36 .016
6.5 0.42 ± 0.48 10.28 ± 0.48 9.17 ± 0.96 .015
*Four mice per treatment were analyzed 2, 4, and 6.5 months, respectively.
†Kruskal-Wallis H test.
‡Data represent the average of the percentage of positive cells in six high-power fields (×10).
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To further evaluate the effects of silica instillation in mouse lungs,
we analyzed the phosphorylation of histone H2AX to indicate the
level of silica-mediated DNA damage present within lung epithe-
lial cells. One hundred percent of lungs from NDMA-silica–treated
mice presented positive p-H2AX staining in hyperplastic areas from
bronchiolar epithelium (n = 6; Figure 1, right panel ). This per-
centage was reduced over time to 50% (month 4; n = 8) and 33%
(month 6.5; n = 3) and disappeared after month 9 (n = 18). Inter-
estingly, p-H2AX was only observed in hyperplastic tissue areas
near to granulomatous areas. None of the lungs from NDMA-
only–treated (n = 28) or saline-treated (n = 20) mice were positive
for p-H2AX. These results indicate that silica promotes DNA dam-
age in lungs. Another important consequence of silica instillation
was, as previously described [19], the development of fibrotic areas
extending to the peripheral and distal regions of the lung in all of the
experimental time points (data not shown). As previously described
[18], we did not detect adenomas nor adenocarcinomas in mice treated
with silica alone.
Chronic Inflammation Increases the Incidence and
Multiplicity of NDMA-Induced Lung Tumors
We next analyzed whether silica-mediated chronic lung inflamma-
tion influences the carcinogenic effects of NDMA. We examined the
preneoplastic and neoplastic lesions in mice treated with saline, silica,
a poorly tumorigenic dose of NDMA, and combination of the same
dose of NDMA and silica. Silica-treatedmice developed chronic inflam-
mation; however, no lung adenomas and adenocarcinomas were
detected at any time during the experiment. However, 75% of mice
treated with NDMA exhibited adenomas after 6.5 months. Pre-
malignant adenomas were detected earlier in mice treated with the
combination of silica and NDMA compared with NDMA-only–
treated mice (4 months after treatment vs 6.5 months, respectively).
Moreover, the incidence and multiplicity of these adenomas were
markedly higher in all of the experimental time points in the combined
treatment group compared with NDMA-only treatment (Figure 2A).
Interestingly, mice treated with the combination of silica and NDMA
also demonstrated a three-fold increase in both incidence and multi-
plicity of lung malignant adenocarcinomas compared with mice treated
with NDMA only (Figure 2B). The ratios of adenocarcinoma to ade-
noma were statistically equivalent: 0.20 ± 0.3 in the combined treat-
ment and 0.12 ± 0.27 in NDMA only (P = .36). Taken together,
these data suggest that silica-mediated local chronic inflammation sig-
nificantly reduces the latency period for the appearance of preneoplastic
lung lesions and strongly promotes lung carcinogenesis.
Lesions in Mice Treated with NDMA and the Combination of
NDMA with Silica Exhibit Similar Histologic and
Molecular Features
Despite an increase in lung cancer incidence and multiplicity in mice
treated with the combination of NDMA and silica, we did not observe
Figure 2. Incidence and multiplicity of adenomas and lung tumors in mice treated with NDMA-only or NDMA-silica. (A) Evaluation of
adenomatous structures at different experimental time points. (B) Quantitation of adenocarcinomas at month 12 after treatment. NDMA-
only–treated mice were analyzed at months 4 (n = 4), 6.5 (n = 4), 9 (n = 4), and 12 (n = 19) after treatment. NDMA-silica–treated mice
were analyzed at months 4 (n = 8), 6.5 (n = 8), 9 (n = 8), and 12 (n = 21) after treatment. Incidence rate was calculated as the
percentage of mice with at least one lung lesion. Multiplicity is represented as the average of the number of lesions found in mouse
lungs ± SEM. P values were calculated using the Kruskal-Wallis test in adenomas, whereas the test chosen for the analysis of adeno-
carcinomas was the Mann-Whitney U test.
Neoplasia Vol. 15, No. 8, 2013 Silicotic Chronic Inflammation and Lung Cancer Freire et al. 917
significant histologic differences between the lesions present in the two
experimental groups (Figure 3, A–H ). Immunohistochemical analysis
of the expression of CC10, an airway Clara cell marker, and pro-SPC, a
type II pneumocyte marker, revealed that adenomas and adenocarci-
nomas from NDMA-only– and NDMA-silica–treated mice were
consistently positive for pro-SPC and negative for CC10, whereas
non-malignant normal and hyperplastic bronchiolar epithelium exhib-
ited positive staining for CCL10, and only hyperplastic alveoli were
positive for pro-SCP (Figure 3, I–P). These data suggest that tumors
are potentially derived from hyperplastic type II cells or less committed
cells following the type II differentiation pathway. Furthermore, we
found no statistical differences in the average size of adenomas (P =
.405) or adenocarcinomas (P = .256) between both experimental
groups. Immunohistochemical analysis of Ki-67 and CD31 revealed
that there was no increase in the proliferative capacity and in the vas-
cular density of adenomas from NDMA-silica when compared to
NDMA-only–treated mice. However, a statistically significant increase
of active caspase-3 immunostaining was found in adenomas from
NDMA-silica–treated mice when compared to those from NDMA-only–
treated mice (P < .001), suggesting that silica promotes apoptosis
within adenomas (Figure W4).
Silica-mediated Chronic Inflammation Modifies the K-RAS
Mutation Profile in NDMA-Induced Lung Tumors
We next evaluated the presence of somatic mutations in oncogenes
and tumor suppressor genes associated with lung carcinogenesis in
humans and mice: K-RAS, STK11, and p53. In particular, we analyzed
activating mutations in K-RAS (codons 12 and 61) and inactivating
mutations in TP53 (exons 5-9) and STK11 (exons 1-5, 8, and 9). This
analysis was performed on DNA from lung adenocarcinomas of mice
treated with NDMA-silica (n = 10) or NDMA only (n = 5). Of the 15
adenocarcinomas studied, 13 exhibited mutation in K-RAS, either in
codon 12 or codon 61. Importantly, the mutational pattern was dif-
ferent between the NDMA-only and NDMA-silica–induced lesions.
Specifically, the K-RAS mutations in tumors that originated following
NDMA-silica treatment was primarily G-to-A transition (G12D) in
codon 12, whereas A-to-G transition (Q61R) in codon 61 was the most
Figure 3. Histopathologic features of lung lesions from NDMA and NDMA-silica–treated mice. All lesions classified as adenomas and
adenocarcinomas in Figure 2 were analyzed. (A–H) Hematoxylin and eosin staining of bronchiolar (A) and alveolar (B) epithelium, a solid
adenoma (C), and a papillary adenocarcinoma (D) from NDMA-treated mice and bronchiolar hyperplasia (E), alveolar epithelium (F), a
solid adenoma (G), and papillary adenocarcinoma (H) from NDMA-silica–treated mice. (I–P) Immunohistochemical analysis of pro-SPC
and CC10 in tumors and adenomas from NDMA-silica– and NDMA-treated mice. Slides were counterstained with Harris’ hematoxylin.
All adenomas (I, M) and adenocarcinomas (J, N) exhibited positive staining for pro-SPC in both NDMA-silica– and NDMA-treated mice.
Adenomas (K, O) and adenocarcinomas (L, P) were negative for CC10 staining in both experimental groups, whereas normal bronchiolar
epithelial cells close to the tumors (*) exhibited CC10 positive staining. Scale bar, 100 μm.
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frequent alteration in adenocarcinomas from mice treated with NDMA
only (P = .031; Figure 4). None of the adenocarcinomas analyzed pres-
ented somatic mutations in p53 and STK11 hotspots.
Silica-induced Chronic Inflammation Exhibits a
Pro-inflammatory Gene Expression Profile
To further characterize the effects of silica-mediated chronic inflam-
mation in lung carcinogenesis, we performed microarray analysis.
Minimal differences in gene expression were found in adenocarcinomas
from NDMA-silica– and NDMA-only–treated mice (Table W2).
However, marked gene expression differences were observed between
NDMA-silica and NDMA-only adenomas. In particular, 36 genes were
upregulated and 13 downregulated in adenomas frommice treated with
NDMA-silica compared to mice treated with NDMA only (Figure 5A
and Table 2). Interestingly, a substantial group of the most relevant
upregulated genes in the NDMA-silica model, such as Saa3, Retnla,
Irg1, Serpina3n, Adam8, and Lta, plays a key role in inflammation.
To confirm this finding at the protein level, we chose one of these
genes, Retnla, upon commercial availability of commercial anti-mouse
specific protein antibody. Retnla expression was analyzed by immuno-
histochemistry (Figure 5B). Most of the adenomas (17 of 23) from
NDMA-silica–treated mice exhibited positive staining for Retnla,
whereas adenomas (11 of 16) from NDMA-only–treated mice were
negative (P = .011). Functional analysis of the genes differentially
expressed in adenomas and adenocarcinomas from both experimental
groups demonstrated differences in the enriched GO categories. In
adenomas, the presence of silica-mediated inflammation affected GO
categories associated with inflammation and immune response, whereas
enriched categories in adenocarcinomas were unrelated to these pro-
cesses (Table W3).
Silica-induced Chronic Inflammation Promotes an
Immunosuppressive Microenvironment in Adenomas
Malignant transformation may be associated with an immuno-
suppressive microenvironment. Using microarray expression data,
we analyzed whether silica-induced chronic inflammation generates
an immunosuppressive microenvironment in adenomas and adeno-
carcinomas in NDMA-treated mice (Figure 6). Genes associated with
immunosuppression, such as PD-1, transforming growth factor–β1
(TGF-β1), lymphocyte-activation gene 3 (LAG3), monocyte chemo-
tactic protein 1 (MCP-1), or FOXP3, presented higher expression
levels in adenomas from NDMA-silica–treated mice compared to mice
treated with NDMA only (Figure 6A). No differences were observed
in the expression of these genes among adenocarcinomas from both
experimental groups (data not shown). Additionally, we assessed the
presence of FOXP3-positive cells within adenomas from mice treated
with NDMA-silica (n = 15) and NDMA only (n = 15) using immuno-
histochemistry. All FOXP3-positive cells analyzed presented lympho-
cyte morphology. Positive FOXP3-positive lymphocytes were counted
separately in the lesions and in the immediate peripheral lung paren-
chyma tissue (the “capsule” of the lesion). We did not observe FOXP3-
positive lymphocytes within adenomas from NDMA-only–treated
mice, whereas 7.1% of adenomas from NDMA-silica–treated mice
exhibited at least one FOXP3-positive lymphocyte (Figure 6B). We
analyzed the FOXP3-positive cells present at the periphery of ade-
nomas; one hundred percent of adenomas from NDMA-silica–treated
mice exhibited at least one FOXP3-positive peripheral lymphocyte,
whereas only 16.5% of adenomas generated following NDMA-only
treatment exhibited at least one FOXP3-positive lymphocyte in the
peritumoral area (Figure 6B).
Finally, we investigated whether silica-induced chronic inflamma-
tion increases the number of FOXP3-positive lymphocytes in distant
lung tissue. We analyzed the presence of FOXP3-positive lympho-
cytes in lymphoid clusters located in non-injured lung areas distant
from adenomas. Twelve percent of NDMA-silica lymphocytes stained
positive for FOXP3 in these distant clusters, whereas only 2.7% were
positive in the NDMA treatment (Figure 6, C andD). Taken together,
these results demonstrate that silica-mediated chronic inflammation pro-
motes the development of an immunosuppressive microenvironment.
Discussion
In this study, we demonstrated that chronic inflammation strongly
promotes lung carcinogenesis in mice. To mimic human lung cancer
in the context of chronic inflammation, we developed for the first
time a chemical-induced carcinogenesis mouse model that comprised
the administration of a low tumorigenic dose of NDMA, a carci-
nogen present in tobacco smoke, in the presence of chronic silica-
induced lung inflammation. Silica is a particulate irritant that induces
pulmonary inflammation in a similar way as other inhaled particles,
such as asbestos [26]. In our study, histologic analysis of the lungs
from silica-treated mice revealed that, as previously described
Figure 4. K-RAS mutational analysis of adenocarcinomas from the NDMA-silica– and NDMA-only–treated mice. (A) Total number of
adenocarcinomas with either K-RAS codon 12 or 61 mutations in NDMA-silica– and NDMA-treated mice. (B) Representative electro-
pherograms showing G-to-A transition in K-RAS codon 12 and A-to-G transition in codon 61. Differences between groups were analyzed
using the Fisher exact test.
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[25,27], this compound triggers a chronic and progressive granulo-
matous lung inflammation accompanied by a systemic increase of pro-
inflammatory cytokines TNF-α, IP-10, and MIP-1α. Importantly, the
analysis of the model at different experimental time points allowed us to
explore in depth preneoplastic and full malignant neoplastic lesions.
Thus, we found that silica-induced chronic lung inflammationmarkedly
increases the incidence and multiplicity of lung adenomas and adeno-
carcinomas following NDMA treatment. These results are in concor-
dance with other animal models that explore the effects of different
inflammatory agents in chemically induced lung tumor promotion.
Continuous administration of butylated hydroxytoluene has been shown
to increase the carcinogenic effects of both 3-methylcholanthrene [28]
and urethane [29]. Exposure to a lysate of Haemophilus influenzae, an
agent that triggers chronic obstructive pulmonary disease–like airway
inflammation, has also been reported to generate a higher incidence of
lung tumors [30]. It has also been demonstrated that inflammation
caused by repetitive exposure to specific levels of tobacco smoke increases
carcinogenesis in both carcinogen-treated mice and in conditional
K-RAS transgenic mice [31].
Chemicals such benzo[a]pyrene, benz[j]aceanthrylene, cyclopenta
[cd ]pyrene, and 3-methylcholanthrene promote K-RAS point
mutations in codons 12 and 13, whereas the predominant mutation
in ethyl carbamate– and urethane-induced lung tumors occurs in
codon 61 [32–36]. In the present study, our findings indicated that
in lung adenocarcinomas from mice treated with NDMA only,
glutamine in codon 61 is replaced by arginine. However, adeno-
carcinomas generated in a silica-mediated inflammation context
exhibit G-to-A transition in codon 12. Interestingly, activation of
K-RAS through transition G12D mutation is strongly associated with
the presence of marked inflammation characterized by the production
of inflammatory chemokines and infiltration of alveolar macrophages
and lymphocytes [37]. In human lung tumors, the most frequent
K-RAS gene alterations are point mutations in codon 12 [38]. Thus,
the pattern of K-RAS mutations in human lung cancer is more similar
to the combined NDMA-silica model compared to the NDMA-only
model. None of the adenocarcinomas analyzed exhibited somatic
mutations in TP53 or STK11; the absence of TP53 mutations is
common in chemically induced mouse tumors [39].
Figure 5. Differentially expressed genes after a comparison of gene expression profiles of adenomas from NDMA and NDMA-silica–
treated mice. (A) Matrix expression of the representative signature for the set of genes differentially expressed (B > 0; ∣log FC∣ > 1.5).
Each line represents the gene expression profile of a mixture of RNA from at least two different adenomas (total n = 14). Red and green
represent upregulated and downregulated genes, respectively, when compared to the corresponding normal lung tissue expression
profile. (B) Retnla negative staining in an NDMA adenoma (left panel) and Retnla positive staining in an NDMA-silica adenoma located
close to silica-induced lung inflammation (right panel). Retnla staining was performed in adenomas from 10 mice treated with NDMA
and 16 mice treated with NDMA-silica. Differences between groups were analyzed using the Fisher exact test.
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The development of an immunosuppressive microenvironment
seems very relevant for malignant transformation and is closely asso-
ciated with chronic inflammation [7].We did not observe differences in
the presence of immunosuppressive genes between adenocarcinomas
from NDMA-only– versus NDMA-silica–treated mice. In contrast,
there were clear differences in the expression of the immunosuppressive
genes PD-1, TGF-β1, MCP-1, LAG3, and FOXP3. PD-1 is an
immunosupressor membrane protein present on activated T cells.
The clinical usefulness of PD-1 blockade by a specific antibody has
recently been demonstrated in patients with advanced non–small cell
lung cancer [14]. TGF-β1 modulates processes such as cell invasion
or immune regulation and thus avoids the protumorigenic effects of
chronic inflammation [40]. Interestingly, blockade of the activity of
TGF-β1 by neutralizing antibodies inhibits lung metastasis in mice
[41]. MCP-1 is a chemokine locally produced by tumors and involved
in the recruitment of inflammatory cells. A high level of MCP-1 pro-
motes tumor macrophage infiltration and correlates with poor progno-
sis and metastatic disease in patients with breast cancer [42]. Inhibition
of MCP-1 significantly improves tumor immunotherapy [43]. Further-
more, these factors (PD-1, TGF-β1, and MCP-1) also exert immuno-
suppressive activities through the promotion of Tregs activities [43–
45]. Tregs are produced in the thymus as a functionally mature T cell
subpopulation [46]. They are important in maintaining immune
tolerance and limiting autoimmunity. However, Tregs also attenuate
immune responses against tumors [47,48]. In fact, the suppressive
activity and number of Tregs are increased in human lung cancer
[49,50]. LAG3 and FOXP3 are two important markers of Tregs.
LAG3 is a CD4-related protein that binds major histocompatibility
complex (MHC) class II and reduces the proliferation of T cells
[51]. FOXP3 is a key regulator of the development and function of
Table 2. Genes Differentially Expressed in Adenomas from NDMA-Silica–Treated Mice versus Adenomas from NDMA-Treated Mice (B 0; ∣log FC∣ 1.5).
Genes Description Log FC P Value B
Upregulated genes
Saa3 Serum amyloid A 3 3.95 .000131 1.15
Tcf7l2 Transcription factor 7-like 2, T cell specific] 3.63 .000109 1.32
S100a8 S100 calcium binding protein A8 (calgranulin A) 3.63 .000001 5.08
Retnla Resistin-like α 3.50 .000015 3.04
Irg1 Immunoresponsive gene 1 3.38 .000434 0.10
S100a9 S100 calcium binding protein A9 (calgranulin B) 3.25 .000009 3.49
Tmco1 Transmembrane and coiled-coil domains 1 3.11 .000196 0.80
Exosc9 Exosome component 9 3.05 .000415 0.14
Adam8 A disintegrin and metallopeptidase domain 8 2.93 .000051 1.97
Gast Gastrin 2.48 .000291 0.45
Stfa3 Stefin A3 2.43 .000126 1.19
Bclp2 Chitinase-like protein 2 2.33 .000462 0.05
Mitf Microphthalmia-associated transcription factor 2.32 .000117 1.25
Hsdl2 Hydroxysteroid dehydrogenase like 2 2.23 .000348 0.30
Ssxa1 Synovial sarcoma, X member A, breakpoint 1 2.22 .000319 0.37
Lta Lymphotoxin A 2.14 .000342 0.31
Ifitm1 Interferon-induced transmembrane protein 1 2.13 .000376 0.23
Lax1 Lymphocyte transmembrane adaptor 1 2.11 .000244 0.61
Galnt6 UDP-N -acetyl-α-D-galactosamine:polypeptide N -acetylgalactosaminyltransferase 6 2.08 .000012 3.20
Myt1l Myelin transcription factor 1-like 2.07 .000468 0.03
Retnlg Resistin-like γ 1.98 .000043 2.13
Adamts15 A disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 15 1.96 .000070 1.70
Bank1 B-cell scaffold protein with ankyrin repeats 1 1.96 .000043 2.13
Mef2c Myocyte enhancer factor 2C 1.94 .000340 0.32
Serpina3n Serine (or cysteine) peptidase inhibitor, clade A, member 3N 1.89 .000014 3.12
Akap13 A kinase (PRKA) anchor protein 13 1.84 .000226 0.68
IGKV3-12 Immunoglobulin κ light chain V gene segment 1.79 .000041 2.16
Nfkbia Nuclear factor of κ light chain gene enhancer in B-cells inhibitor, α 1.72 .000090 1.48
P2ry10 Purinergic receptor P2Y, G-protein coupled 10 1.70 .000123 1.21
Ncf4 Neutrophil cytosolic factor 4 1.68 .000306 0.41
Cyp39a1 Cytochrome P450, family 39, subfamily a, polypeptide 1 1.67 .000257 0.56
Xlr3b X-linked lymphocyte-regulated 3B (Source: MarkerSymbol;Acc:MGI:109505) 1.67 .000459 0.05
Slc36a2 Solute carrier family 36 (proton/amino acid symporter), member 2 1.66 .000075 1.64
Pstpip1 Proline-serine-threonine phosphatase-interacting protein 1 1.59 .000139 1.10
IGKV3-4 Immunoglobulin κ light chain V gene segment 1.52 .000020 2.78
Fhad1 Forkhead-associated (FHA) phosphopeptide binding domain 1 1.52 .000365 0.25
Downregulated genes
Tmem169 Transmembrane protein 169 −1.51 .000281 0.48
Mta1 Metastasis associated 1 −1.63 .000379 0.22
Ppp1r9a Protein phosphatase 1, regulatory (inhibitor) subunit 9A −1.72 .000396 0.18
Ascl3 Achaete-scute complex homolog-like 3 (Drosophila) −1.74 .000317 0.38
Col15a1 Procollagen, type XV −1.75 .000425 0.12
Maff V-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) −1.78 .000225 0.68
Rabgap1l RAB GTPase activating protein 1-like −1.78 .000018 2.88
Etv1 Ets variant gene 1 −2.04 .000038 2.24
Txndc12 Thioredoxin domain containing 12 (endoplasmic reticulum) −2.05 .000275 0.50
Cpox Coproporphyrinogen oxidase −2.40 .000025 2.59
Serpina3c Serine (or cysteine) peptidase inhibitor, clade A, member 3C −2.82 .000158 0.99
Sertad4 SERTA domain containing 4 −2.89 .000012 3.24
Tmem27 Transmembrane protein 27 −3.18 .000049 2.01
Neoplasia Vol. 15, No. 8, 2013 Silicotic Chronic Inflammation and Lung Cancer Freire et al. 921
Tregs [52]. In accordance with previous studies [53], we have found an
increase in the percentage of FOXP3-positive lymphocytes in lymphoid
clusters in mice treated with silica. Importantly, we found a marked
increase of Tregs in preneoplastic lesions in NDMA-silica–
treated mice. The permissive environment provided by FOXP3-
positive T cells is required for K-RAS–mediated tumorigenesis in mice
treated with 4-(N -nitrosomethylamino)-1-(3-pyridyl)1-butanone, a
carcinogen present in tobacco smoke [54]. In addition to promoting
an immunosuppressive microenvironment, silica-induced chronic
inflammation significantly increased apoptosis levels within adenomas
maybe due to the increased DNA damage and the inflammatory stress
triggered by silica administration. Taken together, our findings suggest
that chronic inflammation generates a favorable microenvironment for
the generation of preneoplastic lesions that potentially contributes to
the progression of adenomas to adenocarcinomas.
In summary, in this study, we developed a novel mouse model of
lung cancer that allows for the study of the interaction of chronic
inflammation with lung tumorigenesis. Molecular analysis of this
model reveals some of the underlying mechanisms through which
chronic inflammation facilitates the development of preneoplastic
lesions and, consequently, lung cancer. Elucidation of the interplay
between inflammation and lung carcinogenesis will help in the devel-
opment of preventive strategies to slow down or avoid the generation
of premalignant lesions and the conversion to malignant tumors.
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Figure 6. Expression of different immunomodulators in adenomas from NDMA-silica– and NDMA-treated mice. (A) Signature of immuno-
suppressive genes expressed in adenomas from NDMA-silica–treated mice compared to NDMA-treated mice. Each line represents the
gene expression profile of a mixture of RNA from at least two different adenomas (total n = 14). Upregulated and downregulated genes
are shown in red and green, respectively. (B) Percentage of lesions with FOXP3-positive cells within adenomas and adenoma peripheral
areas (“capsule”) from NDMA-silica–treated (n= 15) and NDMA-treated (n= 15) mice. (C) Percentage of FOXP3-positive lymphocytes to
total lymphocytes counted on lymphoid clusters located in non-injured lung parenchyma areas from NDMA-silica– and NDMA-treated
mice. Values are represented as the means ± SEM. (D) FOXP3 immunohistochemical staining of lymphoid clusters from NDMA- and
NDMA-silica–treated mice. The P value was calculated using the Mann-Whitney U test.
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Table W1. Primers Used for Mutational Analysis of the Mouse K-RAS, TP53, and STK11 Genes
and for IL-6, IL-1β, and GM-CSF mRNA Expression.
Genes Sense 5′→3′ Antisense 5′→3′
K-RAS exon 2 tgtaaggcctgctgaaaatg cgtagggtcatactcatccaca
K-RAS exon 3 tgtgtttctcccttctcagga tgcaggcataacaattagcaa
TP53 exon 5-6 tagttccccaccttgacacc gacgcacaaaccaaaacaaa
TP53 exon 7 tgccgaacaggtggaatatc cagaagctggggaagaaaca
Tp53 exon 8-9 gggggcctagtttacacaca tgcgagagacagaggcaata
STK11 exon 1 aaggggacgaggacaaaga gaagagccagaaagtaggag
STK11 exon 2 caggtgtcacaggcaaacag agcactattgctgccagagg
STK11 exon 3 gagagcagagtggtggtggt acctgggtttcctgacaatg
STK11 exon 4-5 catggtatgggctgagacac cactagggaaaacccacagc
STK11 exon 8 ctgtagccggagcactaagg tcatgttagctggctggaga
STK11 exon 9 gcttgcctttggagctactg cactgtgaacaccagggatg
IL-6 acaaagccagagtccttcag tggatggtcttggtcctta
IL-1β gctgaaagctctccacctca aggccacaggtattttgtcg
GM-CSF caagggcgccttgaacat atgaaatccgcataggtggt
Figure W1. Ilustrative examples of CD4 (CD4 T lymphocytes), CD8 (CD8 T lymphocytes), CD3 (total T lymphocytes), CD20 (B lymphocytes),
myeloperoxidase (polymorphonuclear leukocytes), and CD68 (monocyte/macrophage) immunostainings in lungs from mice treated with
NDMA-only, silica, and NDMA-silica.
Figure W2. Plasma levels of (A) TNF-α, (B) MIP-1α, (C) IP-10, (D) IL-1β, (E) IL-6, (F) GM-CSF, (G) IL-10, (H) IL-13, (I) INF-γ, and (J) IL-12 (p40) in
mice treated with saline (white circles), silica (black triangles), NDMA (white squares), and NDMA-silica (black squares) at different exper-
imental points. Values represent the mean of plasma cytokine concentration from four mice ± SEM. Differences between groups were
analyzed at every experimental point using the Kruskal-Wallis test with post hoc Dunn comparison (n.s., P > .05; **P< .01; ***P< .001).
Figure W3. (A) IL-6, (B) IL-1β, and (C) GM-CSF mRNA expression in lung lobes from mice treated with NDMA-only (eight lung lobes from
eight mice) or NDMA-silica (six lung lobes from three mice) at month 12. The analysis was performed by real-time PCR using specific
primers for all these genes (TableW1).Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as housekeeping gene. Differences
between experimental groups were analyzed using the Mann-Whitney U test (n.s., P > .05; *P< .05; ***P< .001).
Figure W4.Quantitative analysis of proliferation, angiogenesis, and apoptosis of adenomas from NDMA- and NDMA-silica–treated mice.
(A) Proliferation was measured as the number of positive immunostained Ki-67 cells per mm2 of adenomas (NDMA, n = 18 lesions;
NDMA-silica, n = 63 lesions). (B) Angiogenesis was quantified as the percentage of the area of adenoma positive for CD31 immuno-
staining (NDMA, n = 28 lesions; NDMA-silica, n = 74 lesions). (C) Apoptosis level was quantified as the percentage of positive active
caspase-3–immunostained cells (NDMA, n= 28; NDMA-silica, n= 74). Values are represented as the means ± SEM. Differences between
groups were analyzed using a two-sided Mann-Whitney U test (ns, P > .05).
Table W3. List of GO Categories Enriched in the Differentially Expressed Genes of NDMA-Silica Tumors when Compared to the NDMA Tumors.
Term P Value Genes
GO enriched in adenomas
NDMA-silica versus NDMA
Response to external stimulus .000084 Serpina1c, Saa3, C1qc, Hsdl2, S100a8,
Serpina3n, Lta, Etv1, S100a9
Acute inflammatory response .000095 Serpina1c, Saa3, C1qc, Hsdl2, Serpina3n
Inflammatory response .00051 Serpina1c, Saa3, C1qc, Hsdl2, Serpina3n, Lta
Immune system process .00074 Nfkbia, Lax1, C1qc, Hsdl2, H2-Q6,
Lta, Mitf, S100a9, Bank1
Acute-phase response .0028 Serpina1c, Saa3, Serpina3n
Protease inhibitor activity .015 Serpina1c, Stfa3, Stfa3, Serpina3n, Serpina3c
Enzyme binding .026 Nfkbia, Lax1, Pstpip1, Bank1
Positive regulation of biologic process .028 Lax1, C1qc, Col15a1, Lta, Etv1, Mitf, Tcf7l2, Mef2c
Receptor binding .04 C1qc, Lta, Gast, Retnla, Retnlg, Bank1
GO enriched in adenocarcinomas
NDMA-silica versus NDMA
Regulation of cellular process .0074 Cycs, Ston1, Tcf25, Rabgap1l, Plk2, Maff, Ascl3,
Irf6, Etv1, Carm1, Cnot6l, Phf10
Biologic regulation .010 Cycs, Tcf25, Rabgap1l, Ascl3, Maff, Irf6, Cnot6l,
Phf10, Ston1, Plk2, Carm1, Etv1, Npr1
Nucleobase, nucleoside, nucleotide,
and nucleic acid metabolic process
.012 Msh5, Tcf25, Cstf1, Maff, Ascl3, irf6, Etv1,
Carm1, Cnot6l, Npr1, Phf10
Nucleic acid binding .016 Msh5, Tcf25, Cstf1, Rbm12, Maff, Ascl3, irf6,
Etv1, Cnot6l, Phf10
Transcription regulator activity .021 Tcf25, Maff, Ascl3,irf6, Etv1, Carm1
RNA metabolic process .023 Tcf25, Cstf1, Maff, Ascl3, irf6, Etv1, Carm1, Cnot6l, Phf10
Regulation of transcription, DNA-dependent .026 Tcf25, Maff, Ascl3, irf6, Etv1, Carm1, Cnot6l, Phf10
Metabolic process .029 Cycs, Tcf25, Aanat, Ascl3, Maff, irf6, Cnot6l, Phf10,
Msh5, Hunk, Cstf1, Plk2, Mthfd1l, Etv1, Carm1, Npr1
P value is shown for each GO category.
Table W2. Differentially Expressed Genes in Adenocarcinomas from NDMA-silica– and NDMA-Treated Mice* (B 0; |log FC| 1.5).
Genes Description Log FC P Value B
Upregulated genes in NDMA-silica versus
NDMA adenocarcinomas
Hunk Hormonally upregulated Neu-associated kinase 2.07 .0000051 3.68
Dcpp1 Demilune cell and parotid protein 1 1.67 .0000437 1.95
Downregulated genes in NDMA-silica versus
NDMA adenocarcinomas
Maff V-maf musculoaponeurotic fibrosarcoma oncogene family,
protein F (avian)
−1.54 .0003058 0.33
Etv1 Ets variant gene 1 −1.66 .0001147 1.15
Gm1965 Gene model 1965, (NCBI) −1.72 .0000123 2.98
Carm1 Coactivator-associated arginine methyltransferase 1 −1.79 .0002850 0.39
Plk2 Polo-like kinase 2 (Drosophila) −1.87 .0003810 0.15
Tcirg1 T-cell, immune regulator 1, ATPase, H+ transporting,
lysosomal V0 protein A3
−2.06 .0000497 1.84
Kdelc1 KDEL (Lys-Asp-Glu-Leu) containing 1 −2.07 .0001641 0.85
Aanat Arylalkylamine N -acetyltransferase −2.22 .0000979 1.28
Muc4 Mucin 4 −2.65 .0000000 8.69
Tcf25 Transcription factor 25 (basic helix-loop-helix) −3.09 .0000019 4.45
Rbm12 RNA binding motif protein 12 −3.17 .0000019 4.47
Serpina3c Serine (or cysteine) peptidase inhibitor, clade A, member 3C −3.31 .0000060 3.55
*For each candidate P value, B statistic and log FC are shown.
